Biomedicine Daily · Saturday, 17 October 2026
CBA FRONTIER INSIGHTS
The Nobel Prize in Physiology or Medicine 2026: Awarded to Karl Deisseroth, Peter Hegemann, and Georg Nagel "for their discoveries concerning light-gated ion channels and optogenetics"
The 2026 Nobel Prize in Physiology or Medicine goes to Karl Deisseroth, Peter Hegemann and Georg Nagel for discoveries concerning light-gated ion channels and optogenetics. Hegemann and Nagel discovered channelrhodopsin, an algal protein that opens an ion channel under blue light, and Deisseroth turned it into a light-controlled switch for nerve cells, first demonstrated in rat neurons in 2005 and in living mouse brains two years later. The method now underpins work on neural circuits in neurological and psychiatric disorders and attempts to restore sight in visually impaired patients.
Clinical readouts and safety
Lonvoguran Ziclumeran - In Vivo CRISPR Gene Editing in Hereditary Angioedema.
A single intravenous infusion of the in vivo CRISPR gene-editing therapy lonvoguran ziclumeran cut monthly hereditary angioedema attack rates by 87% relative to placebo in a phase 3 trial of 80 patients with C1 inhibitor deficiency. From weeks 5 through 28, the mean monthly attack rate was 0.26 with lonvo-z versus 2.10 with placebo (P<0.001), with no serious or grade 3 or higher adverse events in the treatment group. The results support a one-time infusion replacing ongoing preventive therapy for this disease.
medicalxpress.comPrescribing antidepressants based on patients' genetic makeup does not improve the effectiveness of treatment
Mirikizumab one-year data show steroid-free disease control in ulcerative colitis and Crohn's disease
One year of mirikizumab (Omvoh) produced steroid-free outcomes in two Lilly trials. In LUCENT-2, 27.7% of ulcerative colitis patients achieved comprehensive steroid-free disease control, and in VIVID-1, 20.4% of Crohn's disease patients achieved steroid-free deep remission. The results extend mirikizumab's reported efficacy profile to composite one-year endpoints in both conditions.
EGFR-targeted antibody−toxin conjugate in recurrent glioma: a phase 1 trial
A phase 1 trial of D2C7-ATC, an antibody-toxin conjugate targeting EGFR and EGFRvIII, in patients with recurrent malignant glioma showed encouraging safety and efficacy signals. Translational analyses of patient samples indicated intratumoral and systemic immune activation. The results support the conjugate as a candidate strategy for recurrent malignant glioma.
Regulatory and policy
FDA Approves Roche's Satralizumab for Thyroid Eye Disease in Adults
Roche said on October 16 that the FDA has approved Satralizumab (Enspryng) for treating adults with thyroid eye disease (TED), making it the first and currently only at-home subcutaneous injection option for these patients. Patients or trained caregivers can administer the injection themselves. The approval is the drug's second indication, following NMOSD.
China Proposes Export Controls on Five Biopharmaceutical Technologies Including Cell and Gene Therapy
China's Ministry of Commerce and Ministry of Science and Technology proposed revisions to the catalogue of technologies banned or restricted from export, opening a public consultation on October 16 with pre-export registration for the listed technologies. The revision covers 40 technologies across artificial intelligence, biopharmaceuticals and photovoltaics. Five biopharma technologies would be added: banned for export are original cell and gene therapy process platforms, small nucleic acid drug process platforms, and artificial genetic modification of pathogenic microorganisms with directed passage gain; restricted are new target discovery and validation technologies for cell and gene therapy and for small nucleic acid drugs.
FDA Expedited Investigational New Drug (IND) Pilot Program
The FDA has launched the Expedited IND Pilot Program under HHS Operation TrialBlazer to test ways of shortening the path from IND-enabling activities to first-in-human trials in the US. Sponsors partnering voluntarily with qualified research institutions, which advise on toxicology, clinical and CMC components, can submit IND pieces for rolling FDA review rather than waiting for a complete package. FDA retains full regulatory authority, and the pilot's evidence may shape future policy such as accreditation of these institutions.
FDA Approves New Nonprescription Eye Drop for Relief of Eye Redness
The FDA approved Brytly, apraclonidine ophthalmic solution 0.125%, as the first nonprescription eye drop containing apraclonidine, for relief of eye redness due to minor irritations in adults and children 12 and older. The approval, granted to Alcon, limits use to no more than two times per day. It aligns with FDA priorities to expand access to affordable nonprescription medicines.
CDER Exclusivity Board
FDA's Center for Drug Evaluation and Research has set up an Exclusivity Board to oversee and advise on certain exclusivity determinations, aiming for clarity and consistency. The Board covers 5-year new chemical entity exclusivity, 3-year new clinical trial exclusivity, and biological product exclusivity, but generally will not review 180-day generic drug, 7-year orphan drug, or 6-month pediatric exclusivity. It may also evaluate CDER exclusivity policies and keep records of determinations, and questions can be sent to its FDA email address.
Counterfeit Versions of Eye Drops Found in Several States
The FDA has identified counterfeit over-the-counter eye drops sold in Florida and Georgia stores serving mainly Spanish-speaking customers, with possible presence in Louisiana, Mississippi, North Carolina and other states. Testing found Staphylococcus contamination in counterfeit Colirio Ocusan Alivio rapido del enrojecimiento and unconfirmed bacterial contamination in counterfeit Ocusan Ojos Secos, both labeled as DLC Laboratories products. The FDA is working with distributors to remove the products and its investigation continues; no adverse events have been reported to the agency.
Industry and deals
Next-gen RNAi drugmaker City prices $200M IPO
City Therapeutics raised $200 million in its IPO, selling just over 11.1 million shares at $18 each, and begins Nasdaq trading Friday under ticker CTY. Co-founded by former Alnylam CEO John Maraganore, the company develops RNA interference therapies, with lead candidate CITY-FXI targeting Factor XI for thromboembolic diseases and a first Phase 2 trial in knee-replacement patients expected next year. Its CITY-RBP4 program for Stargardt disease enters Phase 1 later this year, and an anemia of chronic disease program starts an early-stage study in 2027.
biocentury.comOMass’ $310M round among U.K.’s largest ever for a biotech: Venture Report
OrbiMed Closes $3 Billion Across Two Funds, With Asia Fund VI Exceeding $1 Billion
OrbiMed has closed two funds totaling $3 billion: OrbiMed Asia Partners VI and OrbiMed Private Investments X. Asia Partners VI raised over $1 billion for growth equity and venture investments in healthcare, making it OrbiMed's largest Asia-focused fund to date, up from $751 million for Fund V and $800 million for Fund IV.
Estuary sails into kidney disease space with $103M for gene therapies
Estuary Biotherapeutics emerged from stealth with $103 million in financing for two lead gene therapies targeting autosomal dominant polycystic kidney disease (ADPKD). The total comprises a $93 million series A led by RA Capital Management and a $10 million seed from 4BIO Capital and GV. EST-201, a full-length PKD2 gene therapy delivered via AAV, enters the clinic in 2027 in PKD2-mutation ADPKD patients, while AAV-delivered EST-101 is expected to enter the clinic in 2028.
This week in charts: Moderna’s massive stock run
Moderna shares have risen more than 600% in 2026, far outpacing the XBI biotech index fund's 23% gain, after the Phase 3 success in August of intismeran autogene, a melanoma vaccine co-developed with Merck. Analysts say detailed results due at a medical meeting later this month will shape whether the run continues. Separately, Roche has struck five deals with Chinese drugmakers since late August, collectively worth more than $5 billion, spanning obesity candidates and molecular glue drugs.
Research papers
A telomere-to-telomere map of somatic mutation burden and functional impact in a cancer.
Near-telomere-to-telomere diploid assembly of a donor paired with deep short- and long-read sequencing of their melanoma shows that 16% of somatic variants fall in sequences absent from GRCh38, with satellite repeats acting as UV mutagenesis hotspots. Centromere kinetochore binding domains are focal sites of chromosome arm aneuploidy breakpoints and somatic variation, while epigenetic remodeling there appears specific to cancer. The work defines somatic variation invisible to reference-based analyses.
A phenome-wide structural variant map from 467,152 UK Biobank genomes.
A phenome-wide association study of 1.6 million structural variants in whole-genome sequencing data from 467,152 UK Biobank participants detected 28,184 associations with human health outcomes across 13,322 binary, 2,018 quantitative and 2,923 plasma protein traits. Protein quantitative trait loci analysis linked 3,467 SVs to 1,690 proteins, and 82.25% of SVs lay outside the detectable range of prior copy-number variant studies. The work shows structural variants carry phenotypic effects that earlier methods missed.
Extensive restoration of forelimb function in primates with spinal cord injury by neural stem cell transplantation.
Grafts of human embryonic stem cell-derived spinal cord neural stem cells (H9-scNSCs) restored forelimb function after spinal cord injury in primates. Hemisected animals improved 9.2-fold on a skilled hand task versus lesioned controls (P = 2.5 × 10-27), reaching 53.4 ± 19.2% fine object retrieval success, and hemicontused animals improved 2.9-fold (P = 6.3 × 10-8). Grafts extended axons up to 39 mm below the injury and formed synapses with host circuits, with recovery correlating with rehabilitation effort.
An open vision-language model for diverse medical applications.
MedGemma, a collection of medical vision-language foundation models built on Gemma 3, outperforms similarly sized generative models across medical images and text. On out-of-distribution tasks it improves medical image question answering by 2.6-10%, chest X-ray finding classification by 15.5-18.1%, and agentic evaluations by 10.8% over base models. Its medically tuned vision encoder, MedSigLIP, matches or beats many specialized medical image encoders, and fine-tuning MedGemma beats fine-tuning Gemma 3 directly, especially with limited training data.
Elp1 is required for myeloid differentiation and brain repopulation.
A genome-scale screen of around 20,000 genetic perturbations in ex vivo-expanded cultured haematopoietic stem and progenitor cells (cHSPCs) identifies regulators of glia-induced myeloid differentiation and brain microglia repopulation after transplantation. Elp1 emerged as essential for generating myeloid cells, suppressing the unfolded protein response during myeloid specification, though not for maintaining them. The expanded-cHSPC platform makes large-scale genetic interrogation of brain myeloid biology tractable despite scarce primary HSPCs.
medicalxpress.comLab-grown tumors reveal immune cells capable of killing small cell lung cancer
Memory stays strong in old age when this brain enzyme is active
The enzyme PLA2G2F, a phospholipase identified in mouse hippocampus screening, supports cognitive resilience in ageing. Mice lacking the gene showed surging inflammation, neuron degradation and lower spatial-memory scores, while mice with excess Pla2g2f had less inflammation, better-connected neurons and higher memory scores with age. In human donor brains, PLA2G2F activity rose with age and was highest in resilient individuals whose cognition remained intact despite amyloid-beta deposits.
medicalxpress.comLactation drug could reduce breast cancer risk after childbirth, study suggests
Molecular mechanism of residue-specific nucleosome acetylation.
Cryo-EM structures of the Drosophila MSL complex caught during catalysis show how histone H4 lysine 16 is acetylated in a residue-specific way: a stable product state directly visualizes the acetyl group transferred from coenzyme A to H4K16. Cooperative MSL subunits act as a molecular ruler conferring specificity, and recognition of H3K36 trimethylation speeds enzymatic activity, tying MSL function to active gene bodies and Drosophila dosage compensation.
medicalxpress.comHow heart failure reshapes bone marrow to create inflammation-related immune memory
Targeting proteasome composition reprograms tumor-intrinsic inflammation through selective degradation of STAT1
A covalent small molecule that binds a dynamic pocket in the non-catalytic proteasome regulator PSME4 reprograms tumor-intrinsic inflammation. Blocking or reducing PSME4 with the probe and orthogonal genetic perturbations stabilized STAT1, restored interferon-associated transcription, enhanced antigen presentation, and disrupted IL-6/STAT3 signaling, suppressing tumor growth in vivo. The work defines a PSME4-STAT1-STAT3 axis and a framework for drugging non-catalytic proteasome regulators to alter tumor immunity.
The binding of OTULIN restrains LUBAC activity to prevent TNF-driven immunopathology.
A point mutation in OTULIN (OTULINY56A) that disrupts its binding to LUBAC leaves mice viable and free of spontaneous pathology, but highly sensitive to TNF-induced toxicity and to TNF-mediated immunopathology during Listeria monocytogenes infection. The interaction normally limits LUBAC autoubiquitination and Met1-Ub conjugation on non-LUBAC substrates; losing it stabilizes the TNF receptor signaling complex, increases NF-κB signaling, yet protects from TNF-induced apoptosis. The work separates OTULIN-LUBAC binding from OTULIN catalytic function in restraining inflammatory signaling.
Methods and resources
Somatic epimutations cap genetic determinism in the human diploid chromatin epigenome.
Fiber-seq inferred regulatory elements (FIRE) give a more comprehensive and quantitative view of accessible chromatin across the 6 Gbp diploid human genome, correcting biases in existing catalogs. FIRE enables detection of haplotype-selective chromatin accessibility, revealing imprinted elements without parent-of-origin DNA methylation differences, modules allowing escape from X chromosome inactivation, and disrupted TF binding at the HLA locus in immune cells. The work also shows autosomal somatic chromatin epimutations propagate through clonal expansion as mitotically stable, non-genetic regulatory alterations.
Unprecedented atlas explores mitochondria across the tree of life
Scientists mapped mitochondrial proteins across six organisms spanning the eukaryotic tree of life, including five single-celled parasites and one plant. In Giardia lamblia they identified 59 mitochondrial proteins, 27 of them new, and combined data from six organisms with humans and yeasts into 8,619 proteins across 3,199 families, of which 33 families occur in eukaryotic pathogens but not humans, marking candidate drug targets for diseases such as malaria and sleeping sickness.
doi.orgBiotaPredictor: A machine learning framework for predicting drug depletion by the human gut microbiota
BiotaPredictor is a freely accessible web-based machine learning platform that predicts drug depletion by human gut microbiota from molecular structure. A logistic regression model using physicochemical descriptors, trained on an annotated AstraZeneca dataset of 158 compounds alongside an integrated dataset of 522 compounds, correctly classified all compounds in external validation (3 depleted, 9 stable). It enables early triage of compounds at risk of microbiota-mediated loss, informing lead optimization and pharmacokinetic prediction.
Opinion and commentary
Editorial Expression of Concern: Maternal gut bacteria promote neurodevelopmental abnormalities in mouse offspring.
Nature's editors have issued an Expression of Concern on a paper first published online on 13 September 2017 by Sangdoo Kim, Hyunju Kim, Yeong Shin Yim and colleagues, which reported that maternal gut bacteria promote neurodevelopmental abnormalities in mouse offspring. The notice was published on 08 October 2026. Corresponding authors are Gloria B. Choi and Jun R. Huh, with the work spanning UMass Medical School, MIT, Keio and Harvard. The notice does not state the reason.
Translating base editors: a decade of progress from the bench to the clinic
A review in Nature Reviews Drug Discovery marks ten years since base editing, a gene editing technology that installs point mutations with high efficiency and precision, was first reported. It traces the evolution of base editors and their path to clinical translation, covering key advances and remaining challenges. It also surveys the current clinical trial landscape for the technology.
Only time will tell
Chronotherapy, which aligns treatment with the body's internal clock, is moving into clinical trials, and Nature Medicine published a comment on the approach on 16 October 2026. A high-profile retraction in the field has exposed the challenges facing circadian medicine as the concept advances toward clinical testing. The piece examines both the promise and the setbacks of timing drugs to the circadian rhythm.
Perioperative immunotherapy in head and neck squamous cell carcinoma
Also today
19 events that did not make today's daily, one table per category, one row per event. Open a category to expand.
RegulatoryDaraxonrasib · NMPA Approves TCM 1.1 · LB2501 · Lingshi Zhiyuan's RAS G12V TCR4 ▾▴
Filings, acceptances, designations, approvals and withdrawals at a regulator.
- DaraxonrasibUpdateThe broad-spectrum RAS inhibitor daraxonrasib received FDA approval on August 26 for metastatic pancreatic cancer in adults who have received at least one prior systemic therapy or are not suitable for multi-drug combination systemic therapy. Unlike KRAS G12C inhibitors, it covers mutations including G12V, G12D, G13 and Q61, and the article also notes strong efficacy in lung cancer.FDA
- NMPA Approves TCM 1.1UpdateChina's NMPA approved four granule formulations on October 15, 2026: Zihua Wenfei Zhisou Granule, a Class 1.1 TCM innovative drug, plus three Class 3.1 classic-formula TCM products, Wenjing Tang Granule (Shandong Runzhong Pharmaceutical), Shaoyao Gancao Tang Granule and Yiguan Jian Granule, covering respiratory, gynecological, pain and digestive indications. Zihua Wenfei Zhisou Granule will enter the 2026 national reimbursement talks via the off-catalogue pre-application route.NMPA
- LB2501UpdateThe FDA has cleared an IND for Legend Biotech's LB2501, an off-the-shelf in vivo CAR-T therapy designed to generate CD19/CD20 dual-target CAR-T cells in patients through a single infusion. The indication is relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin lymphoma (B-NHL). Per the company's announcement, LB2501 is the first known dual-target in vivo CAR-T to receive FDA IND clearance. The clearance supports a phase 1/2 trial in the United States evaluating safety, tolerability, pharmacokinetics and preliminary efficacy.FDA
- Lingshi Zhiyuan's RAS G12V TCRUpdateLingshi Zhiyuan's ES502 injection, a TCR-T cell engager, received implicit NMPA clinical trial clearance on October 14, 2026 for advanced solid tumors with RAS G12V mutations. The product had already obtained a US FDA IND on March 12, 2026, completing dual China-US IND filings and enabling parallel clinical development in both regions. The company says ES502 offers stronger tumor specificity and a wider therapeutic window than traditional small-molecule RAS inhibitors.NMPA
ClinicalLIVMARLI · VS-7375 · NeoVax · VQW-765 …6 ▾▴
Trial starts, early and mid-stage data, and results that did not make the daily.
- LIVMARLIUpdateLIVMARLI (maralixibat) delivered positive topline results in the Phase III EXPAND study, a randomized, double-blind, placebo-controlled trial enrolling 52 patients with ultra-rare cholestatic liver diseases including biliary atresia: 46 children and 6 adults, all aged 6 months and older with cholestatic pruritus. Mirum Pharmaceuticals plans to submit a supplemental marketing application in the first half of 2027.
- VS-7375UpdateThe oral KRAS G12D inhibitor VS-7375 showed a confirmed objective response rate of 50% (4/8) in second-line pancreatic ductal adenocarcinoma in the phase 1/2 TARGET-D 101 study. Across second-line and later patients, confirmed ORR was 41% (9/22), with two complete responses, one confirmed. Among 48 patients on 900 mg once daily monotherapy, 2% discontinued due to adverse events and grade 3 treatment-related adverse events occurred in 10%, with no clinically meaningful cumulative toxicity observed.
- NeoVaxUpdateA personalized neoantigen long-peptide vaccine (NeoVax with poly-ICLC), combined with delayed anti-PD-1 antibody, was feasible and safe in ten patients with platinum-sensitive high-grade epithelial ovarian cancer after platinum doublet chemotherapy. Nine of twelve evaluable Cohort B patients were vaccinated (75%, 90% CI 47-93%), over 70% of targets remained detectable in cell-free DNA despite a median 6.5-month biopsy-to-vaccine interval, and biomarker analysis suggested biologic activity in six of ten patients. Resistant tumor clones showed defects in antigen presentation, consistent with vaccine-driven immune pressure.
- VQW-765UpdateVQW-765, an α7-nAChR partial agonist licensed by Vanda Pharmaceuticals from Novartis, missed its primary endpoint in the Phase III study VP-VQW-765-3201 (Study 3201) in adults with social anxiety disorder. Phase II results had shown numerically lower stress levels versus placebo in subjects with a history of performance anxiety, with effects strongest in women.
- MVA-SARS-2-SUpdate
- Osivax focuses on combo strategy for flu vaccine after phase 2 failUpdate
Deals and financingRoche Licenses Rona Therapeutics ALK7 RNAi Obesity Drug in $1.16 Billion Deal · Chai Discovery Signs Six Big Pharma Companies in Nine Months as AI Models Become the Deal · insitro and AstraZeneca Strike Global Exclusive AI Drug Discovery Collaboration for MASH and Cardiom · CSL ← Alentis …9 ▾▴
Licensing, M&A and financing that did not make the daily.
- Roche Licenses Rona Therapeutics ALK7 RNAi Obesity Drug in $1.16 Billion DealUpdateRoche has secured a global exclusive license from China's Rona Therapeutics for an RNA interference drug targeting Activin Receptor-Like Kinase 7 (ALK7) to treat obesity and related metabolic diseases. The deal carries a potential total value of $1.16 billion plus sales royalties. It follows GSK's licensing of an ALK7 program from China's Shi'an Biotech in May 2026, marking another billion-dollar entry into this emerging weight-loss target.
- Chai Discovery Signs Six Big Pharma Companies in Nine Months as AI Models Become the DealUpdateChai Discovery, a San Francisco AI protein and antibody design company founded in March 2024 with no drug pipeline of its own, has signed seven deals with six top pharma companies in nine months, including Pfizer, Novartis, argenx, Bristol Myers Squibb, Eli Lilly and, in early October 2026, GSK. Rather than buying pipelines, the companies are licensing access to Chai's models, with Lilly and Pfizer also obtaining models trained on their proprietary data. Chai raised $400 million in July 2026 at a valuation approaching $3.8 billion, and its third-generation model Chai-3 claims a success rate double that of Chai-2, which hit about 16 percent across 52 de novo protein design targets.
- insitro and AstraZeneca Strike Global Exclusive AI Drug Discovery Collaboration for MASH and CardiomUpdateAI drug discovery company insitro has entered a global exclusive research collaboration with AstraZeneca on October 15 to discover new targets and develop candidates for MASH and cardiomyopathy. insitro receives a $40 million upfront payment and is eligible for up to about $1.46 billion in R&D and commercialization milestone payments plus single-digit royalties on future global sales. insitro will use its Virtual Human platform to identify disease-driving mechanisms and advance AstraZeneca-nominated targets to development candidate stage, while AstraZeneca handles clinical development, regulatory filings and commercialization.
- CSL ← AlentisUpdateCSL and Alentis Therapeutics have struck a global collaboration worth up to roughly $1.6 billion to develop lixudebart, a monoclonal antibody targeting Claudin-1, a protein linked to tissue barriers, cell signaling and organ fibrosis. The programme will focus on rare kidney diseases and liver diseases, where inflammation and fibrosis drive pathology. Further details on trial plans and deal milestones were not disclosed.
- IambicUpdate
- MatchpointUpdateMatchpoint Therapeutics, a biotechnology company focused on precision covalent drug discovery using machine learning and proteomics, has closed a $150 million Series B financing announced on October 7, 2026. Kanishka Pothula, managing partner at Nextech Invest, and Brian Matesic of Norwest will join the company's board. The funds will support its covalent drug development programmes.
- Armed Cell Therapies ← GalapUpdate
- NorthStar Partners with Quark Pharma to Expand CommercialUpdateNorthStar Medical Technologies and Quark Pharma struck a strategic collaboration on October 14, 2026, covering regulatory filings in China for no-carrier-added actinium-225. Quark Pharma will act as NorthStar's registration agent in China, supporting IND filings for drug developers running clinical studies with NorthStar's n.c.a. Ac-225. NorthStar is the first company to produce n.c.a. Ac-225 at commercial scale using electron accelerator technology.
- KindevaUpdate